scholarly article | Q13442814 |
P50 | author | Bette Korber | Q30505218 |
Renate Kunert | Q51764661 | ||
Dennis R. Burton | Q56331320 | ||
Christos J Petropoulos | Q84542015 | ||
P2093 | author name string | Meng Wang | |
James M Binley | |||
Susan Zolla-Pazner | |||
Michael B Zwick | |||
Colombe Chappey | |||
Terri Wrin | |||
Hermann Katinger | |||
Gabriela Stiegler | |||
P2860 | cites work | Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines | Q24531479 |
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 | ||
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro | Q24563642 | ||
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 | ||
Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 | Q27469855 | ||
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design | Q27634018 | ||
Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity | Q27640463 | ||
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D | Q27643126 | ||
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein | Q28140278 | ||
Complete nucleotide sequence of the AIDS virus, HTLV-III | Q28259080 | ||
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin | Q28264707 | ||
Antibody neutralization and escape by HIV-1 | Q29547345 | ||
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination | Q29616724 | ||
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. | Q30416612 | ||
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. | Q30423779 | ||
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes | Q30706865 | ||
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. | Q31016969 | ||
Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion | Q32127339 | ||
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates | Q33603494 | ||
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression | Q33604871 | ||
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins | Q33783353 | ||
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes | Q33783763 | ||
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. | Q33786382 | ||
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes | Q33787329 | ||
Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities | Q33795045 | ||
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection | Q33825654 | ||
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. | Q33835295 | ||
Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedure | Q38942024 | ||
The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases | Q38976321 | ||
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. | Q39090313 | ||
An infectious DNA clone of HIV type 1 subtype C. | Q39257045 | ||
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain | Q39313963 | ||
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. | Q39358702 | ||
Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate | Q39484956 | ||
Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV | Q39550518 | ||
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region | Q39602963 | ||
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor | Q39686562 | ||
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. | Q39868309 | ||
Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site | Q39875133 | ||
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. | Q39879382 | ||
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. | Q40038304 | ||
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. | Q40832863 | ||
Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker | Q40883803 | ||
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein | Q40937092 | ||
Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. | Q40991774 | ||
Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. | Q41065899 | ||
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120 | Q41078744 | ||
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | Q41151327 | ||
Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. | Q41171978 | ||
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. | Q41419602 | ||
Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120 | Q41632477 | ||
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein | Q41645847 | ||
The antibody response in HIV-1 infection. | Q41694946 | ||
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. | Q41714439 | ||
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria | Q42692037 | ||
Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. | Q43610425 | ||
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. | Q43872744 | ||
Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. | Q43951264 | ||
Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. | Q44102674 | ||
Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. | Q44160155 | ||
Determining neutralization serotypes of HIV type 1 by neural networks | Q44391893 | ||
Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies | Q45168377 | ||
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. | Q45662866 | ||
Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies | Q45670204 | ||
Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors | Q45699140 | ||
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. | Q45736635 | ||
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins | Q45762836 | ||
Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates | Q45763324 | ||
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay | Q45766845 | ||
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
International collaboration comparing neutralization and binding assays for monoclonal antibodies to simian immunodeficiency virus | Q45786878 | ||
HIV-1 nomenclature proposal. | Q48750867 | ||
HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and Characterization | Q56921434 | ||
Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials | Q58038926 | ||
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 | Q58038933 | ||
HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral Strains | Q58415406 | ||
Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies 2G12 and 2F5 | Q61554599 | ||
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains | Q67967850 | ||
Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen | Q71848107 | ||
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
Interfering With Inflammation During Cell-Cell Interaction | Q93606952 | ||
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development | Q33842152 | ||
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. | Q33870236 | ||
Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus | Q33925746 | ||
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity | Q33961624 | ||
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
Understanding the genetic diversity of HIV-1. | Q34087006 | ||
Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. | Q34145199 | ||
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria | Q34171212 | ||
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D | Q34323863 | ||
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa | Q34332009 | ||
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells | Q34338761 | ||
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics | Q34415921 | ||
Neutralizing antiviral antibody responses | Q34419527 | ||
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. | Q34445941 | ||
Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. | Q34619876 | ||
Antibodies, viruses and vaccines | Q34810301 | ||
Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions | Q34977075 | ||
Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion | Q34977118 | ||
Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments. | Q35155451 | ||
HIV vaccines 1983-2003. | Q35166836 | ||
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody | Q35170702 | ||
Antibody protection: passive immunization of neonates against oral AIDS virus challenge. | Q35172885 | ||
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. | Q35839973 | ||
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. | Q35849408 | ||
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus | Q35849627 | ||
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i | Q35853761 | ||
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. | Q35854300 | ||
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. | Q35857331 | ||
Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa | Q35860840 | ||
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization | Q35872254 | ||
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 | Q35880498 | ||
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor | Q35890867 | ||
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. | Q35894716 | ||
A vaccine for HIV type 1: the antibody perspective | Q36037760 | ||
Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. | Q36366296 | ||
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies | Q36620408 | ||
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. | Q36623941 | ||
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. | Q36628256 | ||
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. | Q36633402 | ||
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies | Q36634439 | ||
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. | Q36634499 | ||
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization | Q36635390 | ||
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies | Q36638240 | ||
Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies. | Q36673577 | ||
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody | Q36687562 | ||
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation | Q36783052 | ||
Multivariate analysis of human immunodeficiency virus type 1 neutralization data | Q36808080 | ||
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. | Q36954472 | ||
A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago | Q37250834 | ||
Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the amsterdam population. | Q38507860 | ||
Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and C | Q38889279 | ||
Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates | Q38900264 | ||
P433 | issue | 23 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | antibody | Q79460 |
monoclonal antibody | Q422248 | ||
virus | Q808 | ||
virology | Q7215 | ||
P304 | page(s) | 13232-52 | |
P577 | publication date | 2004-12-01 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | |
P478 | volume | 78 |
Q42247165 | 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime |
Q33547451 | 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms |
Q36483956 | 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response |
Q27655865 | A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies |
Q34204188 | A General Approach for Receptor and Antibody-Targeted Detection of Native Proteins Utilizing Split-Luciferase Reassembly |
Q35566508 | A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens |
Q27675032 | A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield |
Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
Q45409784 | A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. |
Q36149102 | A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. |
Q34741807 | A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection |
Q39733091 | A covalent HIV vaccine: is there hope for the future? |
Q28743092 | A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein |
Q33954392 | A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus |
Q57920783 | A dynamic three-step mechanism drives the HIV-1 pre-fusion reaction |
Q34396912 | A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 |
Q27485578 | A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies |
Q36748055 | A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 |
Q31132248 | A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. |
Q34172295 | A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice |
Q27649541 | A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 |
Q33786140 | A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy |
Q33653774 | A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays |
Q37102810 | A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide |
Q34463861 | A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop |
Q36827883 | A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization |
Q45888461 | A vaccine that delivers rather than induces antibodies |
Q37694976 | Accessing the human repertoire for broadly neutralizing HIV antibodies |
Q35077704 | Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic |
Q64253147 | Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV |
Q36099376 | Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection |
Q27489000 | Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates |
Q36600380 | Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. |
Q38342167 | Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop |
Q33272711 | An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 |
Q35109028 | An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus |
Q33820645 | An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120 |
Q40359188 | Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates |
Q33526340 | Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals |
Q37033400 | Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals |
Q40147993 | Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis |
Q33377024 | Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site |
Q28752503 | Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes |
Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
Q27489392 | Antibodies against viruses: passive and active immunization |
Q36141515 | Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens |
Q37127735 | Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine |
Q36759899 | Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG |
Q30843874 | Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. |
Q38293417 | Antibody recognition of HIV and dengue glycoproteins |
Q35024202 | Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo |
Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
Q90677040 | Antibody responses to the HIV-1 envelope high mannose patch |
Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
Q24536059 | Antibody vs. HIV in a clash of evolutionary titans |
Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
Q42738983 | Antibody-based HIV-1 vaccines: recent developments and future directions |
Q35658856 | Antibody-based protection against HIV infection by vectored immunoprophylaxis |
Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
Q56837789 | Anticardiolipin Antibodies in HIV Infection Are Independently Associated with Antibodies to the Membrane Proximal External Region of gp41 and with Cell‐Associated HIV DNA and Immune Activation |
Q38884485 | Anticipating policy considerations for a future HIV vaccine: a preliminary study |
Q35785338 | Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy |
Q36403587 | Antigenic conservation and immunogenicity of the HIV coreceptor binding site |
Q37547245 | Antigenic properties of the HIV envelope on virions in solution |
Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
Q35933555 | Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins |
Q35580892 | Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate |
Q30375834 | Appreciating HIV type 1 diversity: subtype differences in Env. |
Q34774808 | Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines |
Q33667654 | Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions |
Q34008699 | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. |
Q36248882 | Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes. |
Q40145762 | Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope |
Q27680125 | Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 |
Q34008741 | B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses |
Q34597300 | Back to the future: covalent epitope-based HIV vaccine development |
Q35689608 | Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions |
Q35192937 | Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site |
Q39896978 | Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins |
Q39240591 | Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. |
Q33780524 | Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines |
Q35973601 | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells |
Q35164477 | Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals |
Q37438127 | Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies |
Q33614495 | Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables |
Q36174694 | Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization |
Q36697992 | Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania |
Q29615361 | Broad neutralization coverage of HIV by multiple highly potent antibodies |
Q33417195 | Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope |
Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
Q35785010 | Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor |
Q36571900 | Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo |
Q38707583 | Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response |
Q38065391 | Broadly neutralizing antibodies against HIV-1: templates for a vaccine |
Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
Q33444658 | Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers |
Q35012462 | Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L |
Q22242739 | CCR5 monoclonal antibodies for HIV-1 therapy |
Q39084604 | CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection |
Q36469664 | CD4 binding determinant mimicry for HIV vaccine design |
Q37998496 | Candidate antibody-based therapeutics against HIV-1. |
Q37426039 | Carbohydrate vaccines: developing sweet solutions to sticky situations? |
Q24655912 | Catalytic antibodies to HIV: physiological role and potential clinical utility |
Q34229664 | Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies |
Q44176443 | Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection |
Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
Q38947061 | Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia. |
Q40834595 | Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques |
Q37072702 | Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. |
Q34988326 | Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses |
Q34594591 | Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization. |
Q35164416 | Co-expression of foreign proteins tethered to HIV-1 envelope glycoprotein on the cell surface by introducing an intervening second membrane-spanning domain |
Q34807480 | Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers |
Q30994182 | Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes |
Q33984309 | Comparing antigenicity and immunogenicity of engineered gp120. |
Q33867353 | Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease |
Q34663118 | Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques |
Q54209545 | Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China. |
Q44106801 | Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China |
Q37456637 | Complement and antibodies: a dangerous liaison in HIV infection? |
Q38673539 | Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. |
Q34934438 | Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18 |
Q37153097 | Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms |
Q27663325 | Conserved structural elements in the V3 crown of HIV-1 gp120 |
Q28554907 | Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene |
Q30369026 | Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. |
Q34543052 | Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. |
Q37329415 | Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. |
Q37671423 | Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities |
Q33274285 | Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies |
Q36105782 | Cross-reactive broadly neutralizing antibodies: timing is everything |
Q36747750 | Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens |
Q37445549 | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins |
Q37256644 | Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 |
Q27661588 | Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction |
Q27657585 | Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody |
Q42031529 | Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity |
Q27657377 | Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications |
Q36415785 | Current advances and challenges in HIV-1 vaccines |
Q33840789 | Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds |
Q57226425 | Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies |
Q27684578 | Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization |
Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
Q34094476 | Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies |
Q38739398 | Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies |
Q40430180 | Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration |
Q35060140 | Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system |
Q41933100 | Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells |
Q33827798 | Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production |
Q91528949 | Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations |
Q33780961 | Dimeric 2G12 as a potent protection against HIV-1. |
Q42850455 | Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity |
Q47765958 | Directed Evolution of Glycopeptides Using mRNA Display |
Q41879689 | Directed evolution of 2G12-targeted nonamannose glycoclusters by SELMA. |
Q35092308 | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies |
Q35124652 | Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12. |
Q35857221 | Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors |
Q52689038 | Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion. |
Q38962226 | Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope |
Q29617562 | Distribution and three-dimensional structure of AIDS virus envelope spikes |
Q64079873 | Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain |
Q37644030 | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. |
Q37336404 | Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection |
Q33504556 | Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation |
Q90281664 | Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8 |
Q33571825 | Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein |
Q35101333 | Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques |
Q33431668 | Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library |
Q27664711 | Elicitation of structure-specific antibodies by epitope scaffolds |
Q38989627 | Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines |
Q36956100 | Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1 |
Q46108373 | Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes |
Q33313394 | Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. |
Q80146188 | Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes |
Q37344582 | Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo |
Q35076987 | Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected |
Q33888559 | Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects |
Q45406304 | Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. |
Q33883887 | Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 |
Q34819651 | Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic |
Q34648079 | Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 |
Q35785164 | Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations |
Q36388754 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape |
Q33518005 | Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies |
Q33676640 | Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model |
Q37183108 | Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. |
Q35033324 | Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. |
Q36802333 | Exploiting the defensive sugars of HIV-1 for drug and vaccine design |
Q45351263 | Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes |
Q34175370 | Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity |
Q79316750 | Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1 |
Q47547492 | FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS. |
Q37033294 | Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection |
Q34717733 | Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1 |
Q46545827 | Fc receptor but not complement binding is important in antibody protection against HIV. |
Q36081789 | Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization |
Q35491705 | Feline immunodeficiency virus (FIV) neutralization: a review |
Q80150785 | Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope |
Q36192967 | Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. |
Q36814871 | Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41 |
Q33911809 | Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses |
Q37033269 | Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies |
Q40289677 | Functional Contacts between MPER and the Anti-HIV-1 Broadly Neutralizing Antibody 4E10 Extend into the Core of the Membrane |
Q35168642 | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. |
Q40127843 | Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion |
Q33749206 | Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission |
Q36171855 | Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates |
Q33558279 | Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 |
Q35914553 | Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees |
Q44666638 | Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). |
Q35140032 | Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa |
Q34800408 | Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China |
Q35843775 | Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example |
Q43611862 | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies |
Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
Q34392963 | Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies |
Q39824069 | Glycosylation site-specific analysis of clade C HIV-1 envelope proteins |
Q60300930 | Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant |
Q36249933 | HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions |
Q27026662 | HIV broadly neutralizing antibody targets |
Q39806672 | HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase |
Q37851950 | HIV vaccines: progress to date. |
Q33887674 | HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. |
Q33552488 | HIV-1 and influenza antibodies: seeing antigens in new ways |
Q34990575 | HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans |
Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
Q34399542 | HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile |
Q44942815 | HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120. |
Q35640998 | HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies |
Q33869882 | HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies |
Q37405645 | HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses |
Q27000480 | HIV-1 neutralizing antibodies: understanding nature's pathways |
Q34485336 | HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies |
Q41918917 | HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites |
Q34243456 | HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form |
Q41823383 | HIV-2 neutralization by intact V3-specific Fab fragments |
Q39539756 | HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line |
Q39617158 | Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence |
Q33920519 | High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz |
Q38732360 | High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12. |
Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
Q27676155 | Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure |
Q29307502 | Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope |
Q36757139 | Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice |
Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
Q37247974 | Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm |
Q29619015 | Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies |
Q37051645 | Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma |
Q37388409 | Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors |
Q36171536 | Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. |
Q39108796 | Identification and specificity of broadly neutralizing antibodies against HIV |
Q35592911 | Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual |
Q34428738 | Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. |
Q40128614 | Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. |
Q45419055 | Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection |
Q40415206 | Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization |
Q34229329 | Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa |
Q36736610 | Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody |
Q37250899 | Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state |
Q41925820 | Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. |
Q37842335 | Immunotherapeutic restoration in HIV-infected individuals |
Q37729781 | Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. |
Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
Q36949880 | Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response |
Q36804634 | Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination |
Q39783358 | Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection |
Q41936036 | In vitro inhibition of HIV-1 replication in autologous CD4(+) T cells indicates viral containment by multifactorial mechanisms. |
Q34974016 | In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge |
Q35947769 | In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. |
Q33725718 | In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 |
Q36496923 | Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. |
Q33392865 | Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing |
Q44138330 | Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. |
Q52896722 | Induction of antibodies binding to the membrane proximal external region of gp36 of HIV-2. |
Q34517381 | Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. |
Q34983331 | Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. |
Q37789226 | Inhibition of HIV-1 entry: multiple keys to close the door |
Q33897480 | Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region |
Q28469023 | Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B |
Q27658138 | Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity |
Q39265131 | Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections |
Q39843176 | Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype |
Q36103090 | Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens |
Q37245921 | Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes |
Q46078929 | Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. |
Q34630446 | Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody |
Q46310805 | Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies |
Q34206171 | Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. |
Q33374701 | Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 |
Q34648499 | Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). |
Q40113932 | Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. |
Q34784621 | MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide |
Q34681455 | MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. |
Q35857254 | Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies |
Q34157802 | Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine |
Q36107520 | Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin |
Q33910507 | Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120 |
Q35260162 | Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies |
Q37410770 | Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment |
Q37208595 | Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. |
Q46441250 | Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes. |
Q42576275 | Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies |
Q36127736 | MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency |
Q42241364 | Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling |
Q35029737 | Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide |
Q36981930 | Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy |
Q34071790 | Molecular evolution of HIV-1 CRF01_AE Env in Thai patients |
Q33372270 | Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. |
Q35635418 | Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites |
Q36404752 | Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120. |
Q35904501 | Monoclonal antibody-based candidate therapeutics against HIV type 1. |
Q84974132 | Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1 |
Q47218587 | Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. |
Q34712503 | Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA |
Q36475897 | Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins |
Q41844960 | Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus |
Q36099045 | N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization |
Q36565090 | N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus |
Q35864051 | N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03 |
Q34434854 | Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. |
Q89548775 | Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization |
Q34304203 | Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. |
Q45421316 | Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity |
Q34301874 | Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant |
Q38864042 | Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda. |
Q40909337 | Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection |
Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
Q39206567 | Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India |
Q45460445 | Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. |
Q33382060 | Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection |
Q36837324 | Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark |
Q37252676 | Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge |
Q34550046 | Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success |
Q39934862 | Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity |
Q47566038 | Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells |
Q35208657 | Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination |
Q33887693 | Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? |
Q37971867 | Neutralizing antibodies and control of HIV: moves and countermoves. |
Q34055377 | Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production |
Q81816292 | Neutralizing antibodies take a swipe at HIV in vivo |
Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
Q24655129 | Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors |
Q34651668 | Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses |
Q35826306 | Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane |
Q35275117 | Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs |
Q36414162 | Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. |
Q21089590 | Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 |
Q37417794 | Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens |
Q33693391 | Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. |
Q37099857 | Origin and biology of simian immunodeficiency virus in wild-living western gorillas |
Q30358434 | Passive immunization against HIV/AIDS by antibody gene transfer. |
Q38954558 | Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody |
Q37034639 | Perspectives for a protective HIV-1 vaccine |
Q37105366 | Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database |
Q40239519 | Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model |
Q37220020 | Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. |
Q30402036 | Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning |
Q36694846 | Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates |
Q38023086 | Plant made anti-HIV microbicides--a field of opportunity |
Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
Q37094429 | Polyvalent AIDS vaccines |
Q45417687 | Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. |
Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
Q33895810 | Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. |
Q35415717 | Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults |
Q35124761 | Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method |
Q38343551 | Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates |
Q33702217 | Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection |
Q38206519 | Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). |
Q56892297 | Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice |
Q34551010 | Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate |
Q40043685 | Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design |
Q36384117 | Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors |
Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
Q51830138 | Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. |
Q42215329 | Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. |
Q38574172 | Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction |
Q37584635 | Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. |
Q33725673 | Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
Q29619511 | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 |
Q35603504 | Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. |
Q37119451 | Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination |
Q51802993 | Recognition and blocking of HIV-1 gp41 pre-transmembrane sequence by monoclonal 4E10 antibody in a Raft-like membrane environment. |
Q33911935 | Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines |
Q40766118 | Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. |
Q36837815 | Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization |
Q45365167 | Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence |
Q34357068 | Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. |
Q40204965 | Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. |
Q38632078 | Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function |
Q28075274 | Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design |
Q35635163 | Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection |
Q39723388 | Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization |
Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
Q33898131 | Role of humoral immunity in host defense against HIV. |
Q41019767 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults |
Q36184440 | Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations |
Q41933070 | Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines |
Q33262382 | Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning |
Q34456367 | Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China |
Q36634965 | Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes |
Q36638489 | Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals |
Q40311562 | Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma |
Q34103170 | Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions |
Q37084521 | Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses |
Q40397998 | Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis |
Q34415389 | Specificity of the autologous neutralizing antibody response |
Q35065249 | Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic |
Q30784057 | Statistical approaches to analyzing HIV-1 neutralizing antibody assay data |
Q27658173 | Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens |
Q57292375 | Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan |
Q36281210 | Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10. |
Q35122067 | Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 |
Q27681352 | Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope |
Q36856960 | Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors |
Q27650903 | Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set |
Q27649247 | Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization |
Q34987048 | Structure-based vaccine design in HIV: blind men and the elephant? |
Q34353296 | Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody |
Q35196671 | Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design |
Q34128200 | Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. |
Q34499013 | Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity |
Q36424523 | Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins |
Q37704735 | Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection |
Q35947805 | Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies |
Q37143743 | Sustained release of proteins from a modified vaginal ring device. |
Q37333743 | T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces |
Q37246321 | Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies |
Q37179763 | Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding |
Q34146546 | The MHC class II cofactor HLA-DM interacts with Ig in B cells |
Q33883936 | The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner |
Q42013922 | The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. |
Q36898696 | The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. |
Q36483346 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection |
Q30367176 | The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. |
Q52581587 | The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. |
Q45362788 | The effect of human immunodeficiency virus type 1 (HIV-1) gp41 variability on antibody detection |
Q85228912 | The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies |
Q57460198 | The expanding array of HIV broadly neutralizing antibodies |
Q40051843 | The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen |
Q35140408 | The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population |
Q28275986 | The good and evil of complement activation in HIV-1 infection |
Q37099851 | The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions |
Q40414065 | The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles |
Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
Q36384607 | The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation. |
Q36497712 | The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design |
Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
Q35644971 | The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization |
Q39822146 | The six-helix bundle of human immunodeficiency virus Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn |
Q42185150 | Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. |
Q33614365 | Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies |
Q57697548 | Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques |
Q37962848 | Toward automated oligosaccharide synthesis |
Q37431843 | Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity |
Q37348636 | Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. |
Q33826682 | Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain |
Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
Q35857683 | Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. |
Q92538999 | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
Q34178341 | Very few substitutions in a germ line antibody are required to initiate significant domain exchange. |
Q35948073 | Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. |
Q30603475 | Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography |
Q33772637 | Which Antibody Functions are Important for an HIV Vaccine? |
Q24567758 | bNAber: database of broadly neutralizing HIV antibodies |
Search more.